Pol Sisó Camarasa

Dr. Pol Sisó Camarasa

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CBCarla Barceló
Carla Barceló
PCPol Sisó Camarasa
Pol Sisó Camarasa
OMOscar Maiques
Oscar Maiques
SGSandra García-Mulero
Sandra García-Mulero
RSRebeca Sanz-Pamplona
Rebeca Sanz-Pamplona
AMAnna Macià
Anna Macià

8 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CBCarla Barceló
Carla Barceló
PCPol Sisó Camarasa
Pol Sisó Camarasa
OMOscar Maiques
Oscar Maiques
IRInés de la Rosa
Inés de la Rosa
RMRosa M Marti
Rosa M Marti
AMAnna Macià
Anna Macià
T-type calcium channels (TTCCs) are overexpressed in several cancers. In this review, we summarize the recent advances and new insights into TTCC biology, tumor progression, and prognosis biomarker and therapeutic potential in the melanoma field. We describe a novel correlation between the Cav3.1 isoform and the increased basal autophagy in BRAFV600E-mutant melanomas and after acquired resistance to BRAF inhibitors. Indeed, TTCC blockers reduce melanoma cell viability and migration/invasion in vitro and tumor growth in mice xenografts in both BRAF-inhibitor-sensitive and -resistant scenarios. These studies open a new, promising therapeutic approach for disseminated melanoma and improved treatment in BRAFi relapsed melanomas, but further validation and clinical trials are needed for it to become a real therapeutic option.

18 November 2023 in STAR Protocols
Verified
Journal Article
Open access
PCPol Sisó Camarasa
Pol Sisó Camarasa
IRInés de la Rosa
Inés de la Rosa
CRChristopher Ríos
Christopher Ríos
APAnaïs Panosa
Anaïs Panosa
JVJoan Verdaguer
Joan Verdaguer
AMAnna Macià
Anna Macià
Here, we present a protocol to study and describe immune cells that surround or infiltrate tumor cells or get through the body of a melanoma syngeneic mice model. We describe steps for creating and establishing the syngeneic mouse model, euthanasia, and tumor or organ harvest. We then detail procedures to rapidly achieve a single-cell suspension from different tissue samples to further quantify and analyze the phenotype of the immune cell population (lymphocytes T and B, tumor-associated macrophages, and myeloid-derived suppressor cells) by flow cytometry.

Verified
Journal Article
Open access
PDF file
IRInés de la Rosa
Inés de la Rosa
PCPol Sisó Camarasa
Pol Sisó Camarasa
CMChristopher Ríos Martínez
Christopher Ríos Martínez
JGJudith Gracia
Judith Gracia
DCDolors Cuevas
Dolors Cuevas
AMAnna Macià
Anna Macià
Acral lentiginous melanoma (ALM) is a rare melanoma subtype primarily located in acral regions. However, ALMs exhibit a distinctive genetic profile characterized by a high number of copy number variations (CNVs) and limited point mutations. Late diagnosis and restricted therapeutic efficacy contribute to its poor prognosis. The secretome within the tumor microenvironment (TME) influences immune modulation and plays a vital role in melanoma progression. We aim to analyze the role of ALM secretome and CNVs profile with prognosis in primary ALM patients. Here, we demonstrated that high CNV burden (CNVsHigh) was associated with worse clinicopathological characteristics and poor prognosis. Furthermore, our study also revealed that conditioned media (CM) of CNVsHigh genetic profile ALM cell line was associated with pro-tumoral, pro-angiogenic, and immunosuppressive secretome profiles. In addition, CM of CNVsHigh cell lines in vitro promotes macrophage polarization to immunosuppressive phenotype. Moreover, we observed an increased presence of immunosuppressive tumor-associated macrophages (TAMs) at the invasive front (IF) of CNVsHigh ALM biopsies. This research reveals the adverse prognostic impact of CNVsHigh in ALM patients, establishing a novel link with a pro-tumor secretome, offering potential biomarkers for prognosis and personalized treatment to enhanced disease monitoring in ALM patients.